​​HIV Functional Cure Momentum Builds as American Gene Technologies Approaches Data Readout

Collage of photos of AGT employees, scientists in the lab, and the AGT office building
Published on :

After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.

Dr. Anthony Fauci & AGT’s Jeff Galvin Join ‘I AM BIO’ to Discuss Future of HIV Treatments

Published on :

EPISODE SUMMARY
For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?
Guests:
Jeffrey Galvin, American Gene Technologies
Anthony Fauci, National Institute of Allergy and Infectious Diseases
EPISODE NOTES
For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?  

Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients

Published on :

Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients “We are here to bring the Community together to change the world!” opened [….]